Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

被引：52

作者：

Muralidharan, G

Fruncillo, RJ

Micalizzi, M

Raible, DG

Troy, SM

机构：

[1] Wyeth Ayerst Res, Dept Clin Pharmacol, Collegeville, PA 19426 USA

[2] Wyeth Ayerst Res, Clin Pharmacol Unit, Philadelphia, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 04期

关键词：

D O I：

10.1128/AAC.49.4.1656-1659.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The pharmacokinetics of tigecycline was evaluated in 46 healthy young and elderly men and women. Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters. Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex.

引用

收藏

页码：1656 / 1659

页数：4

相关论文

共 26 条

[11]

JUSKO WJ, 1992, APPL PHARMACOKINETIC

[12] Age and gender effects on the pharmacokinetics of gatifloxacin [J].

LaCreta, FP ;

Kollia, GD ;

Duncan, G ;

Behr, D ;

Grasela, DM .

PHARMACOTHERAPY, 2000, 20 (06) :67S-75S

[13] Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis [J].

Lefort, AS ;

Lafaurie, M ;

Massias, L ;

Petegnief, Y ;

Saleh-Mghir, A ;

Muller-Serieys, C ;

Le Guludec, D ;

Fantin, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :216-222

[14] CLINICAL PHARMACOKINETICS OF ANTIBACTERIAL DRUGS IN THE ELDERLY - IMPLICATIONS FOR SELECTION AND DOSAGE [J].

MEYERS, BR ;

WILKINSON, P .

CLINICAL PHARMACOKINETICS, 1989, 17 (06) :385-395

[15]

Muck W, 1996, INT J CLIN PHARM TH, V34, P293

[16] Age-dependent changes of the kidneys:: Pharmacological implications [J].

Mühlberg, W ;

Platt, D .

GERONTOLOGY, 1999, 45 (05) :243-253

[17] Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects [J].

Muralidharan, G ;

Micalizzi, M ;

Speth, J ;

Raible, D ;

Troy, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :220-229

[18] Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model [J].

Nannini, EC ;

Pai, SR ;

Singh, KV ;

Murray, BE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :529-532

[19]

NORRBY SR, 1989, REV INFECT DIS, V11, pS1102

[20] In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae [J].

Patel, R ;

Rouse, MS ;

Piper, KE ;

Steckelberg, JM .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) :177-179